Category Filter

Policies & Guidelines

Asset Publisher

Content with Policies & Guidelines Draft Provider-Administered Drug Policies .

Emrelis

Actemra, Tofidence, Tyenne, Avtozma, Tocilizumab-anoh, Tocilizumab-aazg

Aloxi, Posfrea

Eylea, Eylea HD, Opuviz, Yesafili, Ahzantive, Enzeevu, Pavblu

Herceptin; Ogivri; Kanjinti; Trazimera; Herzuma; Ontruzant, Hercessi, Trastuzumab-pkrb

Lupron Depot, Lupron Depot-Ped, Eligard, Fensolvi, Lutrate Depot, Camcevi,  Leuprolide Acetate Depot 

Prolia; Jubbonti; Ospomyv; Stoboclo; Denosumab-dssb; Conexxence; Denosumab-bnht; Xgeva; Wyost; Xbryk; Osenvelt; Bomyntra

Rituxan, Truxima, Ruxience, Riabni

Stelara, Wezlana, Selarsdi, Pyzchiva, Otulfi, Imuldosa, Yesintek, Steqeyma, Ustekinumab-aekn

Trelstar

Velcade, Boruzu, Bortezomib

Zoladex

Krystexxa

Visudyne

Fusilev, Khapzory

Neulasta, Fulphila, Udenyca, Ziextenzo, Nyvepria; Fylnetra, Stimufend, Rolvedon, Ryzneuta, Pegfilgrastim-fpgk

Dysport

Myobloc

Xeomin

Sustol